Aurinia Pharmaceuticals Inc. - Amendment to Schedule 13D Filing

This filing is an amendment to the Schedule 13D for Aurinia Pharmaceuticals Inc., originally filed on September 12, 2024. The amendment, dated March 25, 2026, updates information regarding beneficial ownership. Notably, on March 23, 2026, Kevin Tang was appointed as the Chief Executive Officer of the Issuer. Tang Capital Management LLC, along with associated entities and Kevin Tang, collectively hold 9.2% of the company's common shares, amounting to 12,229,500 shares. This ownership percentage and share count remain unchanged from previous filings. The filing details the shared voting and dispositive power among these entities and individuals. No new transactions or changes in beneficial ownership value are reported in this amendment, beyond the CEO appointment.